ANAB - AnaptysBio Inc
IEX Last Trade
38.1
1.480 3.885%
Share volume: 376,929
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$36.62
1.48
4.04%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-08 | 2023-03-01 | 2023-05-11 | 2023-08-07 | 2023-11-02 | 2024-03-11 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 603.848 M | 618.503 M | 610.383 M | 551.792 M | 517.100 M | 487.326 M | 452.389 M | 405.835 M | |
| Current Assets | 452.809 M | 450.444 M | 447.205 M | 437.154 M | 438.535 M | 428.000 M | 406.835 M | 372.420 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.625 M | 6.298 M | 4.545 M | 4.480 M | 5.867 M | 11.684 M | 9.080 M | 10.666 M | |
| Short Term Investments | 9.625 M | 6.298 M | 4.545 M | 4.480 M | 5.867 M | 11.684 M | 9.080 M | 10.666 M | |
| Total Receivables | 1.033 M | 1.180 M | 1.419 M | 1.523 M | 3.182 M | 3.269 M | 6.851 M | 7.089 M | |
| Current Cash | 442.151 M | 442.966 M | 441.241 M | 431.151 M | 429.486 M | 413.047 M | 390.904 M | 354.665 M | |
| Total Non-current Assets | 151.039 M | 168.059 M | 163.178 M | 114.638 M | 78.565 M | 59.326 M | 45.554 M | 33.415 M | |
| Property Plant Equipment | 2.059 M | 1.972 M | 2.089 M | 1.982 M | 2.023 M | 2.254 M | 2.098 M | 1.954 M | |
| Other Assets | 256.000 K | 256.000 K | 256.000 K | 256.000 K | 256.000 K | 256.000 K | 256.000 K | 256.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 603.848 M | 618.503 M | 610.383 M | 551.792 M | 517.100 M | 487.326 M | 452.389 M | 405.835 M | |
| Total liabilities | 299.542 M | 340.884 M | 348.280 M | 360.699 M | 368.650 M | 366.943 M | 364.286 M | 358.057 M | |
| Total current liabilities | 19.871 M | 21.063 M | 26.054 M | 35.795 M | 41.631 M | 39.178 M | 37.442 M | 32.298 M | |
| Accounts Payable | 1.587 M | 3.006 M | 2.784 M | 3.168 M | 4.761 M | 6.521 M | 4.698 M | 4.582 M | |
| Other liabilities | 261.019 M | 301.586 M | 304.413 M | 307.516 M | 310.073 M | 311.272 M | 310.807 M | 310.184 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 261.019 M | 301.586 M | 304.413 M | 307.516 M | 310.073 M | 311.272 M | 310.807 M | 310.184 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 304.306 M | 277.619 M | 262.103 M | 191.093 M | 148.450 M | 120.383 M | 88.103 M | 47.778 M | |
| Common stock | 28.204 M | 28.289 M | 28.454 M | 27.953 M | 26.629 M | 26.546 M | 26.568 M | 26.801 M | |
| Retained earnings | -390.562 M | -424.064 M | -450.477 M | -494.732 M | -534.577 M | -571.885 M | -614.096 M | -658.032 M |